Latest Insider Transactions at Third Harmonic Bio, Inc. (THRD)
This section provides a real-time view of insider transactions for Third Harmonic Bio, Inc. (THRD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Third Harmonic Bio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Third Harmonic Bio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 26
2024
|
Julie Person CHIEF ADMINISTRATIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$120,000
$12.46 P/Share
|
|
Jun 26
2024
|
Julie Person CHIEF ADMINISTRATIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$40,000
$4.2 P/Share
|
|
Jun 07
2024
|
Jennifer Dittman Chief Development Oper Officer |
SELL
Open market or private sale
|
Direct |
494
-100.0%
|
$6,916
$14.17 P/Share
|
|
Jun 07
2024
|
Jennifer Dittman Chief Development Oper Officer |
SELL
Grant, award, or other acquisition
|
Direct |
494
-50.0%
|
$1,976
$4.2 P/Share
|
|
May 20
2024
|
Jennifer Dittman Chief Development Oper Officer |
SELL
Open market or private sale
|
Direct |
1,042
-100.0%
|
$14,588
$14.0 P/Share
|
|
May 20
2024
|
Jennifer Dittman Chief Development Oper Officer |
SELL
Grant, award, or other acquisition
|
Direct |
1,042
-50.0%
|
$4,168
$4.3 P/Share
|
|
May 16
2024
|
Jennifer Dittman Chief Development Oper Officer |
SELL
Open market or private sale
|
Direct |
23,578
-100.0%
|
$330,092
$14.04 P/Share
|
|
May 16
2024
|
Jennifer Dittman Chief Development Oper Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,578
+36.33%
|
$94,312
$4.25 P/Share
|
|
May 09
2024
|
Natalie C. Holles CEO |
SELL
Open market or private sale
|
Direct |
20,222
-1.63%
|
$242,664
$12.18 P/Share
|
|
May 09
2024
|
Natalie C. Holles CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,222
+1.61%
|
$80,888
$4.2 P/Share
|
|
Apr 11
2024
|
Natalie C. Holles CEO |
SELL
Open market or private sale
|
Direct |
13,558
-1.1%
|
$162,696
$12.19 P/Share
|
|
Apr 11
2024
|
Natalie C. Holles CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,558
+1.09%
|
$54,232
$4.2 P/Share
|
|
Apr 04
2024
|
Julie Person CHIEF ADMINISTRATIVE OFFICER |
SELL
Open market or private sale
|
Direct |
1,107
-100.0%
|
$11,070
$10.0 P/Share
|
|
Apr 04
2024
|
Julie Person CHIEF ADMINISTRATIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,107
+50.0%
|
$4,428
$4.2 P/Share
|
|
Dec 05
2023
|
Julie Person CHIEF ADMINISTRATIVE OFFICER |
SELL
Open market or private sale
|
Direct |
12,863
-100.0%
|
$128,630
$10.3 P/Share
|
|
Dec 05
2023
|
Julie Person CHIEF ADMINISTRATIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
12,863
+50.0%
|
$51,452
$4.2 P/Share
|
|
Dec 05
2023
|
Edward R. Conner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,790
-100.0%
|
$47,900
$10.03 P/Share
|
|
Dec 05
2023
|
Edward R. Conner Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,790
+50.0%
|
$19,160
$4.2 P/Share
|
|
Dec 20
2022
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
214,063
+4.44%
|
$856,252
$4.11 P/Share
|
|
Sep 19
2022
|
David P Bonita |
BUY
Open market or private purchase
|
Indirect |
300,000
+4.94%
|
$5,100,000
$17.0 P/Share
|
|
Sep 19
2022
|
David P Bonita |
BUY
Conversion of derivative security
|
Indirect |
5,479,071
+50.0%
|
-
|
|
Sep 19
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
300,000
+4.94%
|
$5,100,000
$17.0 P/Share
|
|
Sep 19
2022
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
5,479,071
+50.0%
|
-
|
|
Sep 19
2022
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
7,066,470
+44.63%
|
-
|
|
Sep 19
2022
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
300,000
+2.83%
|
$5,100,000
$17.0 P/Share
|